论文部分内容阅读
目的探讨重组人干扰素α-1b雾化吸入治疗毛细支气管炎的疗效。方法选取2012年4月-2015年4月该院收治的120例毛细支气管炎患儿为研究对象。根据患儿入院ID号进行随机选取均分为观察组和对照组各60例。两组患儿均进行常规治疗,对照组在常规治疗基础上,给予患儿异丙托溴铵雾化吸入治疗;观察组在对照组治疗基础上,联合应用重组人干扰素α-1b雾化吸入治疗。治疗后,记录比较两组患儿肺部啰音、三凹征、咳嗽、发热及喘憋改善时间,对比两组患儿的疗效及不良反应状况。结果观察组患儿肺部啰音、三凹征、咳嗽、发热及喘憋改善时间明显短于对照组,差异有统计学意义(t=10.542、3.997、4.971、9.184、4.999,均P<0.05),观察组治疗的总有效率(98.33%)明显高于对照组(85.00%),两组比较差异有统计学意义(χ~2=6.982,P<0.05)。两组不良反应发生率差异无统计学意义(8.33%vs 11.67%,χ~2=0.370,P>0.05)。结论重组人干扰素α-1b雾化吸入治疗毛细支气管炎患儿,疗效显著,安全性良好。
Objective To investigate the therapeutic effect of inhalation of recombinant human interferon α-1b on bronchiolitis. Methods From April 2012 to April 2015, 120 children with bronchiolitis admitted to this hospital were selected as the study objects. According to the children admitted to hospital ID number randomly selected were divided into observation group and control group of 60 cases. The two groups of children were treated routinely, and the control group was treated with ipratropium bromide inhalation therapy on the basis of routine treatment. On the basis of the control group, the observation group was treated with recombinant human interferon α-1b Inhalation therapy. After treatment, the pulmonary rales, triple recess sign, cough, fever and wheezing were recorded and compared in two groups. The curative effect and adverse reaction of the two groups were compared. Results The improvement time of pulmonary rales, triple recess, cough, fever and wheezing in observation group were significantly shorter than those in control group (t = 10.542,3.997,4.971,9.184,4.999, all P <0.05 ). The total effective rate of the observation group was significantly higher than that of the control group (98.33% vs 85.00%, χ ~ 2 = 6.982, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (8.33% vs 11.67%, χ ~ 2 = 0.370, P> 0.05). Conclusions Recombinant human interferon α-1b aerosol inhalation for the treatment of children with bronchiolitis has significant curative effect and good safety.